The development of multiple myeloma treatment is remarkable, but advances in tools that guide personalized treatments based on a patient’s risk are necessary. In this study, we identify the most relevant prognostic biomarkers in patients with newly diagnosed multiple myeloma. Dr.. Juan Jose Garces, a researcher in the multiple myeloma group in Sima and first author of the work, performed within the Hispanic Myeloma/PETHEMA group.
Featured for the third year
This is the third edition of the conference in which a team of researchers from University of Navarra They received the SEHH Best Work Award. “Two years ago, Goicoechea . River demonstrated the role of minimal residual disease studies in determining prognosis and understanding resistance mechanisms in patients with high-risk multiple myeloma.
last year, Catarina da Silva Unravel the clinical and biological significance of dysplastic changes in patients with multiple myeloma at diagnosis,” he recalls. Dr. Bruno Paiva, Co-Director of the Group and Research Member of CIBER de Cáncer (CIBERONC).
“Social media evangelist. Student. Reader. Troublemaker. Typical introvert.”